Moleculin reports FY 2022 net loss of $29.0M; cash $43.1M, runway into Q3 2024

Moleculin Biotech, Inc.

Net loss $29.0M for 2022 vs $6.7M in 2021; R&D expense $19.0M (up $4.6M), G&A $11.5M.
Cash and equivalents $43.1M as of Dec 31, 2022; sufficient to fund ops into Q3 2024.
Annamycin Phase 1/2 trial in AML approved in Italy; first subjects dosed.
FDA granted Fast Track Designation for WP1122 in Glioblastoma Multiforme.
European Phase 1 Annamycin trial reported 80% overall response rate in final cohort.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2022 results: net income $29.0 million.

Period: the fiscal year ended December 31, 2022
Net income: $29.0 million
Result: reported results

Exact text from the filing

The net loss for the year ended December 31, 2022 was $29.0 million, which included non-cash gains of $1.3 million on warrants in 2022 as compared to $6.7 million in the prior year and approximately $2.3 million of stock-based compensation expense in 2022 as compared to $2.4 million in 2021.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-007580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.